Orphan designation: Sorafenib tosilate Treatment of papillary thyroid cancer, 13/11/2013 Expired
Orphan designation: Sorafenib tosilate Treatment of follicular thyroid cancer, 13/11/2013 Expired
Human medicines European public assessment report (EPAR): Sylvant, siltuximab, Date of authorisation: 22/05/2014, Revision: 13, Status: Authorised
Orphan designation: Chimeric anti-interleukin-6 monoclonal antibody (siltuximab) Treatment of Castleman's disease, 30/11/2007 Expired
Human medicines European public assessment report (EPAR): Lamivudine Teva, lamivudine, Date of authorisation: 23/10/2009, Revision: 14, Status: Authorised
Opinion/decision on a Paediatric investigation plan (PIP): Menveo, Meningococcal group A oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenA-CRM) Meningococcal group C oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenC-CRM) Meningococcal group W-135 oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenW-CRM) Meningococcal group Y oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenY-CRM), decision type: W: decision granting a waiver in all age groups for all conditions or indications, therape
It is with great pleasure that we present to you EFIM's Annual Report for the year 2023.
This comprehensive report summarizes multiple achievements, advancements, and milestones we have reached over the past year.
Enjoy reading the full report, which reflects our accomplishments, and remain actively engaged in EFIM activities.
We would like to extend our deepest gratituted to all the EFIM Members involved closely in EFIM activities who have dedicated their time and expertise to the content of this annual report.
EMEA-003370-PIP01-22
EMEA-003364-PIP02-22
EMEA-003339-PIP02-23